Unknown

Dataset Information

0

Synthesis and biological evaluation of pyrazolopyrimidines as potential antibacterial agents.


ABSTRACT: The fragment FOL7185 (compound 17) was found to be a hit against IspD and IspE enzymes isolated from bacteria, and a series of analogs containing the pyrazolopyrimidine core were synthesized. The majority of these compounds inhibited the growth of Burkholderia thailandensis (Bt) and Pseudomonas aeruginosa (Pa) in the Kirby–Bauer disk diffusion susceptibility test. Compound 29 shows inhibitory activity at 0.1 mM (32.2 lg/mL), which is comparable to the control compound kanamycin (48.5 lg/mL). Compound 29 also shows inhibitory activity at 0.5 mM against kanamycin resistant P. aeruginosa. Saturation transfer difference NMR (STD-NMR) screening of these compounds against BtIspD and BtIspE indicated that most of these compounds significantly interact with BtIspE, suggesting that the compounds may inhibit the growth of Bt by disrupting isoprenoid biosynthesis. Ligand epitope mapping of compound 29 with BtIspE indicated that hydrogens on 2,4-dichlorophenyl group have higher proximity to the surface of the enzyme than hydrogens on the pyrazolopyrimidine ring.

SUBMITTER: Goshu GM 

PROVIDER: S-EPMC4764408 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Synthesis and biological evaluation of pyrazolopyrimidines as potential antibacterial agents.

Goshu Gashaw M GM   Ghose Debarati D   Bain Joy M JM   Pierce Phillip G PG   Begley Darren W DW   Hewitt Stephen N SN   Udell Hannah S HS   Myler Peter J PJ   Meganathan R R   Hagen Timothy J TJ  

Bioorganic & medicinal chemistry letters 20151201 24


The fragment FOL7185 (compound 17) was found to be a hit against IspD and IspE enzymes isolated from bacteria, and a series of analogs containing the pyrazolopyrimidine core were synthesized. The majority of these compounds inhibited the growth of Burkholderia thailandensis (Bt) and Pseudomonas aeruginosa (Pa) in the Kirby–Bauer disk diffusion susceptibility test. Compound 29 shows inhibitory activity at 0.1 mM (32.2 lg/mL), which is comparable to the control compound kanamycin (48.5 lg/mL). Com  ...[more]

Similar Datasets

| S-EPMC8296573 | biostudies-literature
| S-EPMC6271455 | biostudies-literature
| S-EPMC9917184 | biostudies-literature
| S-EPMC6269912 | biostudies-literature
| S-EPMC6633193 | biostudies-literature
| S-EPMC6507621 | biostudies-literature
| S-EPMC6320884 | biostudies-other
| S-EPMC4904260 | biostudies-literature
| S-EPMC6099984 | biostudies-literature
| S-EPMC10056909 | biostudies-literature